NASDAQ:ALBO
Delisted
Albireo Pharma Inc Stock News
$44.15
+0 (+0%)
At Close: May 26, 2023
Bank of New York Mellon Corp Has $733,000 Stake in Albireo Pharma Inc (NASDAQ:ALBO)
05:36am, Saturday, 20'th Jun 2020
Bank of New York Mellon Corp boosted its position in shares of Albireo Pharma Inc (NASDAQ:ALBO) by 23.2% in the first quarter, according to the company in its most recent disclosure with the SEC. The
Wall Street Analysts Are Bullish on Top Healthcare Picks - Markets
10:27am, Wednesday, 17'th Jun 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Xenetic Biosciences
Albireo Pharma (ALBO) Received its Third Buy in a Row - Markets
10:13am, Wednesday, 17'th Jun 2020
After Wedbush and Needham gave Albireo Pharma (NASDAQ: ALBO) a Buy rating last month, the company received another Buy, this
Analysts' Top Healthcare Picks: Albireo Pharma (ALBO), Monopar Therapeutics Inc (MNPR) - Markets
05:58pm, Tuesday, 16'th Jun 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Albireo Pharma
Albireo to Host Key Opinion Leader Call on Clinical Outcome Assessments
12:00pm, Wednesday, 10'th Jun 2020
Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that it will host a Key Opinion Leader (KOL) call on clinic
Albireo Announces Two Financing Transactions to Extend Cash Runway Into the Beginning of 2022
11:30am, Tuesday, 09'th Jun 2020
Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced it has agreed to terms with Hercules Capital, Inc. (HTGC) on
Albireo to Present at 2020 Jefferies Virtual Healthcare Conference
12:00pm, Tuesday, 26'th May 2020
BOSTON, May 26, 2020 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that.
The Consensus EPS Estimates For Albireo Pharma, Inc. (NASDAQ:ALBO) Just Fell Dramatically
10:29am, Tuesday, 12'th May 2020
One thing we could say about the analysts on Albireo Pharma, Inc. (NASDAQ:ALBO) - they aren't optimistic, having just...
Albireo Pharma, Inc. (NASDAQ:ALBO) Just Reported And Analysts Have Been Cutting Their Estimates
10:25am, Monday, 11'th May 2020
It's been a good week for Albireo Pharma, Inc. (NASDAQ:ALBO) shareholders, because the company has just released its...
Albireo Pharma, Inc. (ALBO) Q1 2020 Earnings Call Transcript
07:30am, Friday, 08'th May 2020
ALBO earnings call for the period ending March 31, 2020.
Recap: Albireo Pharma Q1 Earnings
11:45am, Thursday, 07'th May 2020
Shares of Albireo Pharma (NASDAQ:ALBO) were flat in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share decreased 60.43% year over year to ($2.23), which may
Albireo Reports Q1 2020 Financial Results and Provides Business Update
11:30am, Thursday, 07'th May 2020
— Commercial preparations advancing, with topline PEDFIC 1 results expected mid-2020 —— First sites initiated for second pivotal trial in biliary atresia —— Management to host.
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
12:00am, Thursday, 07'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 6.)
Adverum Biotechnologies Inc...
How Does Albireo Pharma, Inc. (NASDAQ:ALBO) Affect Your Portfolio Volatility?
12:34pm, Sunday, 03'rd May 2020
If you're interested in Albireo Pharma, Inc. (NASDAQ:ALBO), then you might want to consider its beta (a measure of...
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
12:00am, Sunday, 03'rd May 2020
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
